title: EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy.
abstract: OBJECTIVE
  Approximately 80% of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
  
  
  METHODS
  Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
  
  
  RESULTS
  The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
  
  
  CONCLUSIONS
  Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.
authors.affiliation: Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Kurosaka
authors.forename: Takefumi
authors.initials: T
authors.lastname: Satoh
authors.forename: Edward
authors.initials: E
authors.lastname: Chow
authors.forename: Yuji
authors.initials: Y
authors.lastname: Asano
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Tabata
authors.forename: Masaki
authors.initials: M
authors.lastname: Kimura
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Tsumura
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Ishiyama
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Inoue
authors.forename: Kazushige
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Shiro
authors.initials: S
authors.lastname: Baba
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000150:complications / Q000532:radiotherapy* / Q000556:secondary*; D006801:Humans; D008297:Male; D010146:Pain / Q000150:complications* / Q000532:radiotherapy*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology*; D011788:Quality of Life; D013326:Strontium Radioisotopes / Q000627:therapeutic use
chemical_list: D013326:Strontium Radioisotopes; D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen